Will ‘Descovy’ change paradigm in HIH treatment?
‘Gilead,’ an international biopharmaceutical company, is currently working hard.
It has decided to launch ‘Descovy(generic name: emtricitabine/tenofovir alafenamide),’ the first HIV backbone treatment containing a TAF substance, with the health insurance benefit on the 1st of June only in 10 day...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
